Optimizing Aminoglycoside Use

Critical Care Clinics

Volumn 27, Issue 1, 2011, Pages 107-121

  Craig, William A ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Aminoglycosides; Combination chemotherapy; Gram negative infections; Minimum inhibitory concentration

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; BETA LACTAM; CEFTAZIDIME; CEFUROXIME; GENTAMICIN; NETILMICIN; OFLOXACIN; RIBOSOME RNA; TICARCILLIN; TOBRAMYCIN; VANCOMYCIN;

ABDOMINAL INFECTION; AREA UNDER THE CURVE; BACTEREMIA; BURN; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CRITICALLY ILL PATIENT; DRUG USE; FEBRILE NEUTROPENIA; FEVER; GRAM NEGATIVE INFECTION; HOSPITAL INFECTION; HUMAN; NEPHROTOXICITY; OTOTOXICITY; PARALYSIS; PELVIC INFLAMMATORY DISEASE; PERITONITIS; PNEUMONIA; PRIORITY JOURNAL; PYELONEPHRITIS; REVIEW; SEPSIS; URINARY TRACT INFECTION;

AMINOGLYCOSIDES; ANIMALS; BACTERIAL INFECTIONS; DRUG ADMINISTRATION SCHEDULE; HUMANS; INTENSIVE CARE UNITS;

EID: 78649924909     PISSN: 07490704     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccc.2010.11.006     Document Type: Review

References (89)

1. Leibovici L., Paul M., Poznanski O., et al. Monotherapy versus β-lactam-aminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study. Antimicrob Agents Chemother 1997, 41:1127-1133.
2. Paul M., Soares-Weiser K., Leibovici L. β-lactam monotherapy versus ß-lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. BMJ 2003, 326:1111-1120.
3. Paul M., Benuri Silbigern I., Soares-Weisern K., et al. β-lactam monotherapy versus β-lactam-aminoglycoside combination therapy for treating sepsis. BMJ 2004, 328:668-682.
4. Kumar A., Zarychanski R., Light B., et al. Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis. Crit Care Med 2010, 38:1773-1785.
5. Craig W.A., Gudmundsson S. Postantibiotic effect. Antibiotics in laboratory medicine 1996, 296-329. Williams and Wilkins, Baltimore (MD), chapter 8. 4th edition. V. Lorian (Ed.).
6. Park M.K., Muhvich K.H., Myers R.A.M., et al. Hyperoxia prolongs the aminoglycoside-induced postantibiotic effect in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1991, 35:691-695.
7. Craig W.A., Redington J., Ebert S.C. Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections. J Antimicrob Chemother 1991, 27(Suppl C):29-40.
8. Blaser J., Stone B.B., Zinner S.H. Efficacy of intermittent versus continuous administration of netilmicin in a two-compartment in vitro model. Antimicrob Agents Chemother 1985, 27:343-349.
9. Blaser J., Stone B.B., Groner M.C., et al. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother 1987, 31:1054-1060.
10. Vogelman B., Gudmundsson S., Leggett J., et al. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis 1988, 158:831-847.
11. Hocquet D., Vogne C., Garch El, et al. MexXY-OprM efflux pump is necessary for a adaptive resistance of Pseudomonas aeruginosa to aminoglycosides. Antimicrob Agents Chemother 2003, 47:1371-1375.
12. Xiong Y.Q., Caillon J., Kergueris M.F., et al. Adaptive resistance of Pseudomonas aeruginosa induced by aminoglycosides and killing kinetics in a rabbit endocarditis model. Antimicrob Agents Chemother 1997, 41:823-826.
13. Moore R.D., Lietman P.S., Smith C.R. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1998, 155:93-99.
14. Smith P.F., Ballow C.H., Booker B.M., et al. Pharmacokinetics and pharmacodynamics of aztreonam and tobramycin in hospitalized patients. Clin Ther 2001, 23:1231-1244.
15. Mouton J.W., Jacobs N., Tiddens H., et al. Pharmacodynamics of tobramycin in patients with cystic fibrosis. Diagn Microbiol Infect Dis 2005, 52:123-127.
16. Burkhardt O., Lehmann C., Madabush R., et al. Once-daily tobramycin in cystic fibrosis: better for clinical outcomes than thrice-daily tobramycin but more resistance development. J Antimicrob Chemother 2006, 58:822-829.
17. Kashuba A.D., Nafziger A.N., Drusano G.L., et al. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by Gram-negative bacteria. Antimicrob Agents Chemother 1999, 43:623-629.
18. Powell S.H., Thompson W.L., Luthe M.A., et al. Once-daily vs. continuous aminoglycoside dosing: efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin and tobramycin. J Infect Dis 1983, 147:918-932.
19. Kapusnik J.E., Sande M.A. Novel approaches for the use of aminoglycosides: the value of experimental models. J Antimicrob Chemother 1986, 17(Suppl A):7-12.
20. Pechere M., Letarte R., Pechere J.C. Efficacy of different dosing schedules of tobramycin for treating murine Klebsiella pneumoniae bronchopneumonia. J Antimicrob Chemother 1987, 19:487-491.
21. Querioz M.L.S., Bathirunathan N., Mawer G.E. Influence of dosage interval on the therapeutic response to gentamicin in mice infected with Klebsiella pneumoniae. Chemotherapy 1987, 33:68-76.
22. Craig W.A. Once-daily versus multiple-daily dosing of aminoglycosides. J Chemother 1995, 7(Suppl 2):47-52.
23. Mouton J.W., van Ogtrop M.L., Andes D., et al. Use of pharmacodynamic indices to predict efficacy of combination therapy in vivo. Antimicrob Agents Chemother 1999, 43:2473-2478.
24. Ferriols-Lisart R., Alos-Alminana M. Effectiveness and safety of once-daily aminoglycosides: a meta-analysis. Am J Health Syst Pharm 1996, 53:1141-1150.
25. Freeman C.D., Strayer A.H. Mega-analysis of meta-analysis: and examination of meta-analysis with an emphasis on once-daily aminoglycoside comparative trials. Pharmacotherapy 1996, 16:1093-1102.
26. Kale-Pradhan P.B., Habowski S.R., Chase H.C., et al. Once-daily aminoglycosides: a meta-analysis of nonneutropenic and neutropenic adults. J Pharm Technol 1998, 14:22-29.
27. Galloe A.M., Graudal N., Christensen H.R., et al. Aminoglycosides: single or multiple daily dosing? A meta-analysis on efficacy and safety. Eur J Clin Pharmacol 1995, 48:39-43.
28. Hatala R., Dinh T., Cook D.J. Once-daily aminoglycoside dosing in immunocompetent adults: a meta-analysis. Ann Intern Med 1996, 124:717-723.
29. Munckhof W.J., Grayson M.L., Turnidge J.D. A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses. J Antimicrob Chemother 1996, 37:645-663.
30. Barza M., Ioannidis J.P.A., Cappelleri J.C., et al. Single or multiple daily doses of aminoglycosides: a meta-analysis. BMJ 1996, 312:338-345.
31. Ali M.Z., Goetz M.B. A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 1997, 24:796-809.
32. Bailey T.C., Little J.R., Littenberg B., et al. A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 1997, 24:786-795.
33. Rougier F., Ducher M., Maurin M., et al. Aminoglycoside dosages and nephrotoxicity: quantitative relationships. Clin Pharm 2003, 42:493-500.
34. Rybak M.J., Abate B.J., Kang S.L., et al. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother 1999, 43:1549-1555.
35. Hansen M., Christrup L.L., Jarlov J.O., et al. Gentamicin dosing in critically ill patients. Acta Anesthesiol Scand 2001, 45:734-740.
36. Drusano G.L., Ambrose P.G., Bhavnani S.M., et al. Back to the future: using aminoglycosides again and how to dose them optimally. Clin Infect Dis 2007, 45:753-760.
37. Demczar D.J., Nafziger A.N., Bertino J.S. Pharmacokinetics of gentamicin at traditional versus high doses: implications for once-daily aminoglycoside dosing. Antimicrob Agents Chemother 1997, 41:1115-1119.
38. Aroney R.S., Dalley D.N., Levi J.A. Treatment of serious systemic infections with netilmicin in combination with other antibiotics. Med J Aust 1981, 1:475-477.
39. Maller R., Ahrne H., Holmen C., et al. Once- versus twice-daily amikacin regimen: efficacy and safety in systemic Gram-negative infections. J Antimicrob Chemother 1993, 31:939-948.
40. Ehrmann S., Mercier E., Vecellio L., et al. Pharmacokinetics of high-dose nebulized amikacin in mechanically ventilated healthy subjects. Intensive Care Med 2008, 34:755-762.
41. Bailey D.N., Briggs J.R. Gentamicin and tobramycin binding to human serum in vitro. J Anal Toxicol 2004, 28:187-189.
42. Panidis D., Markantonis S.L., Boutzouka E., et al. Penetration of gentamicin into the alveolar lining fluid of critically ill patients with ventilator-associated pneumonia. Chest 2005, 128:545-552.
43. Carcas A.J., García-Satué J.L., Zapater P., et al. Tobramycin penetration into epithelial lining fluid of patients with pneumonia. Clin Pharmacol Ther 1999, 65:245-250.
44. Zaske D.E., Sawchuk R.J., Gerding D.N., et al. Increased dosage requirements of gentamicin in burn patients. J Trauma 1976, 16:824-828.
45. Gilbert D.N., Bennett W.M. Use of antimicrobial agents in renal failure. Infect Dis Clin North Am 1989, 3:517-531.
46. Pea F., Viale P., Pavan F., et al. Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy. Clin Pharm 2007, 46:997-1038.
47. Traynor A.M., Nafziger A.N., Bertino J.S. Aminoglycoside dosing weight correction factors for patients of various body sizes. Antimicrob Agents Chemother 1995, 39(2):545-548.
48. Schentag J.J., Jusko W.J. Gentamicin persistence in the body. Lancet 1977, 1:486.
49. Nagai J., Tanaka H., Nakanishi N., et al. Role of megalin in renal handling of aminoglycosides. Am J Physiol Renal Physiol 2001, 281:F337-F344.
50. Schmitz C., Hilpert J., Jacobson C., et al. Megalin deficiency offers protection from renal aminoglycoside accumulation. J Biol Chem 2002, 277:618-622.
51. El Mouedden M., Lkaurent G., Mingeot-Leclercq M.P., et al. Apoptosis in renal proximal tubules of rats treated with low doses of aminoglycosides. Antimicrob Agents Chemother 2000, 44:665-675.
52. Servais H., Jossin Y., Van Bambeke F., et al. Gentamicin causes apoptosis at low concentrations in renal LLC-PK1 cells subjected to electroporation. Antimicrob Agents Chemother 2006, 50:1213-1221.
53. Luft F.C., Aronoff G.R., Evan A.P., et al. The renin-angiotensin system in aminoglycoside-induced acute renal failure. J Pharmacol Exp Ther 1982, 220:433-439.
54. Winslade N.E., Adelman M.H., Evans E.S., et al. Single dose accumulation kinetics of tobramycin and netilmicin in normal volunteers. Antimicrob Agents Chemother 1987, 31:605-609.
55. Denamur S., Van Bambeke F., Mingeot-Leclercq M.P., et al. Apoptosis induced by aminoglycosides in LCC-PK1 cells: comparative study of neomycin, gentamicin, amikacin, and isepamicin using electroporation. Antimicrob Agents Chemother 2008, 52:2236.
56. Kahlmeter G., Dahlager J.I. Aminoglycoside toxicity-a review of clinical studies published between 1975 and 1982. J Antimicrob Chemother 1984, 13(Suppl A):9-22.
57. Bertino J.S., Booker L.A., Franck P.A., et al. Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring. J Infect Dis 1993, 167:173-179.
58. Dulon D., Aran J.-M., Zajic G., et al. Comparative uptake of gentamicin, netilmicin, and amikacin in the guinea pig cochlea and vestibule. Antimicrob Agents Chemother 1986, 30:96-100.
59. Moore R.D., Lerner S.A., Levine D.P. Nephrotoxicity and ototoxicity of aztreonam versus aminoglycoside therapy in seriously ill non-neutropenic patients. J Infect Dis 1992, 165:683-688.
60. Brummett R.E., Fox K.E. Aminoglycoside-induced hearing loss in humans. Antimicrob Agents Chemother 1989, 33:797-800.
61. Beaubien A.R., Ormsby E., Bayne A., et al. Evidence that amikacin ototoxicity is related to total perilymph area under the concentration-time curve regardless of concentration. Antimicrob Agents Chemother 1991, 35:1070-1074.
62. Fischel-Ghodsian N. Genetic factors in aminoglycoside toxicity. Ann N Y Acad Sci 1999, 884:99-109.
63. Xing G., Chen Z., Wei Q., et al. Mitochondrial 12S rRNA A827G mutation is involved in the genetic susceptibility to aminoglycoside ototoxicity. Biochem Biophys Res Commun 2006, 346:1131-1135.
64. Sha S- H., Qiu J.H., Schacht J. Aspirin attenuates gentamicin-induced hearing loss. N Engl J Med 2006, 354:1856-1857.
65. Warner W.A., Sanders E. Neuromuscular blockade associated with gentamicin therapy. JAMA 1971, 215:1153-1154.
66. Holtzman J.L. Gentamicin and neuromuscular blockade. Ann Intern Med 1976, 84:55.
67. Wong J., Brown G. Does once-daily dosing of aminoglycosides affect neuromuscular function?. J Clin Pharm Ther 1996, 21:401-411.
68. Weber-Carstens S., Deja M., Koch S., et al. Risk factors in critical illness myopathy during the early course of critical illness: a prospective observational study. Crit Care 2010, 14:186.
69. Moellering R.C. In vitro antibacterial activity of the aminoglycoside antibiotics. Rev Infect Dis 1983, 5(Suppl 2):212-220.
70. Guimaraes M.A., Sage R., Noone P. The comparative activity of aminocyclitol antibiotics against 773 aerobic Gram-negative rods and staphylococci isolated from hospitalized patients. J Antimicrob Chemother 1985, 16:555-562.
71. Price K.E., Kresel P.A., Farchione L.A., et al. Epidemiological studies of aminoglycoside resistance in the USA. J Antimicrob Chemother 1981, 8(Suppl A):89.
72. Gerding D.N., Larson T.A. Aminoglycoside resistance in Gram-negative bacilli during increased amikacin use. Am J Med 1985, 79(1A):1-7.
73. Bengtsson S., Bernarder S., Brorson J.E., et al. In vitro aminoglycoside resistance of Gram-negative bacilli and staphylococci isolated from blood in Sweden 1980-1984. Scand J Infect Dis 1986, 18:257.
74. Martinez J.A., Cobos-Triqueros N., Soriano A., et al. Influence of empiric therapy with a beta-lactam alone or combined with an aminoglycoside on prognosis of bacteremia due to gram-negative microorganisms. Antimicrob Agents Chemother 2010, 54:3590-3596.
75. Micek S.T., Welch E.C., Khan J., et al. Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to Gram-negative bacteria: a retrospective analysis. Antimicrob Agents Chemother 2010, 54:1742-1748.
76. Lepper P.M., Held T.K., Schneider E.M., et al. Clinical implications of antibiotic-induced endotoxin release in septic shock. Intensive Care Med 2002, 28:824-833.
77. Sjolin J., Goscinski G., Lundholm M., et al. Endotoxin release from Escherichia coli after exposure to tobramycin; dose-dependency and reduction in cefuroxime-induced endotoxin release. Clin Microbiol Infect 2000, 6:74-81.
78. Goscinski G., Lundholm M., Odenholt I., et al. Variation in the propensity to release endotoxin after cefuroxime exposure in different gram-negative bacteria: uniform and dose-dependent reduction by the addition of tobramycin. Scand J Infect Dis 2003, 35:40-46.
79. Toky V., Sharma S., Bramhne H.G., et al. Antibiotic-induced release of inflammatory mediators from bacteria in experimental Klebsiella pneumoniae-induced sepsis. Folia Microbiol (Praha) 2005, 50:167-171.
80. Cosgrove S.E., Vigliani G.A., Campion M., et al. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin Infect Dis 2009, 48:713-721.
81. Hughes D.W., Frei C.R., Maxwell P.R., et al. Continuous versus intermittent infusion of oxacillin for treatment of infectious endocarditis caused by methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother 2009, 53:2014-2019.
82. Donowitz G.R., Mandell G.L. Empiric therapy for pneumonia. Rev Infect Dis 1983, 5(Suppl 1):40-48.
83. Safdar N., Handelsman J., Maki D.G. Does combination intravenous antibiotic therapy reduce mortality in Gram-negative bacteremia? A meta-analysis. Lancet Infect Dis 2004, 4:519-527.
84. Ghannam D.E., Rodrigues G.H., Raad I.I., et al. Inhaled aminoglycosides in cancer patients with ventilator-associated Gram-negative bacterial pneumonia: safety and feasibility in the era of escalating drug resistance. Eur J Clin Microbiol Infect Dis 2009, 28:253-259.
85. Czosnowski Q.A., Wood G.C., Magnotti L.J., et al. Adjunctive aerosolized antibiotics for treatment of ventilator-associated pneumonia. Pharmacotherapy 2009, 29:1054-1060.
86. Bailey J.A., Virgo K.S., Dipiron J.T., et al. Aminoglycosides for intra-abdominal infection: equal to the challenge?. Surg Infect (Larchmt) 2002, 3:315-335.
87. Falagas M.E., Matthaiou D.K., Karveli E.A., et al. Meta-analysis: randomized controlled trials of clindamicin/aminoglycoside vs. β-lactam monotherapy for the treatment of intra-abdominal infections. Aliment Pharmacol Ther 2006, 25:537-556.
88. Vidal L., Gafter-Gvili A., Borok S., et al. Efficacy and safety of aminoglycoside monotherapy: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 2007, 60:247-257.
89. Leibovici L., Vidal L., Paul M. Aminoglycoside drugs in clinical practice: an evidence-based approach. J Antimicrob Chemother 2009, 63:246-251.